#United States #New York #Class Action #Gross Law Firm #BioAge Labs

Gross Law Firm Informs BioAge Labs Shareholders

The Gross Law Firm has officially reached out to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA) regarding a class action lawsuit that could potentially impact their investment. This legal action arises from events surrounding BioAge’s initial public offering (IPO) and subsequent announcements that raised safety concerns related to their lead product candidate, azelaprag.

Context of the Lawsuit

The class action is aimed at shareholders who purchased shares of BIOA during a specified period following the IPO on September 26, 2024. The lawsuit stems from BioAge’s announcement on December 6, 2024, that it would halt the STRIDES Phase 2 trial for azelaprag. The firm cited elevated liver transaminase levels in trial participants as the reason, which came as a significant surprise, given the earlier expectations highlighted during the IPO.

Before this announcement, BioAge had positioned azelaprag as a promising option for patients undergoing treatment for obesity with incretin drugs. Following the adverse news, the company's stock plummeted dramatically from $20.09 on December 6 to just $4.65 the following day, resulting in serious financial losses for investors.

Important Deadlines

Shareholders are encouraged to act quickly, with the deadline for registration in this class action lawsuit set for March 10, 2025. Those who wish to participate do not need to be appointed as lead plaintiffs but should register their information to secure their place in the legal process. Once registered, investors will have access to a portfolio monitoring service that will provide updates on the case's progress.

Register your information here.

The Role of the Gross Law Firm

The Gross Law Firm is a well-respected entity in the realm of class action lawsuits, committed to advocating for investors’ rights. Their actions aim to ensure that companies uphold fair business practices and social responsibility. They are dedicated to securing recoveries for investors who have suffered losses due to misleading information or omitted crucial material facts.

Shareholders of BioAge Labs who are affected by this situation are urged to register and stay informed about the developments in this case. The firm emphasizes that participation does not involve any cost or obligation on the part of the investors.

Contact Information

For any inquiries or further details, shareholders can reach out to the Gross Law Firm, located at 15 West 38th Street, 12th floor, New York, NY, 10018. They can be contacted through email at info@grosslawfirm.com or by phone at (646) 453-8903.

As investors navigate the complexities of this legal landscape, it is critical for them to be proactive in securing their interests and staying informed throughout the lawsuit process.

This class action serves as a reminder of the importance of transparency and accountability within the corporate environment, especially in matters directly impacting investor confidence and financial stability.